CoLucid Pharmaceuticals Announces Pricing of Initial Public Offering
May 06 2015 - 8:00AM
CoLucid Pharmaceuticals, Inc. ("CoLucid") (Nasdaq:CLCD), a Phase 3
clinical-stage biopharmaceutical company that is developing its
lead product candidate, lasmiditan, for the acute treatment of
migraine headaches, announced today the pricing of its initial
public offering of 5,500,000 shares of common stock at a public
offering price of $10.00 per share.
In addition, CoLucid has granted the underwriters a 30-day
option to purchase up to an additional 825,000 shares of common
stock at the public offering price to cover over-allotments, if
any. All shares of the common stock in this offering are being sold
by CoLucid. CoLucid's shares are expected to begin trading on The
NASDAQ Global Market on May 6, 2015 under the ticker symbol
"CLCD." This offering is expected to close on May 11, 2015,
subject to customary closing conditions.
Piper Jaffray & Co. and Stifel are acting as joint
book-running managers for the offering. William Blair &
Company, L.L.C. is acting as lead manager and Ladenburg Thalmann is
acting as co-manager for the offering.
A registration statement relating to the securities being sold
in this offering was declared effective by the U.S. Securities and
Exchange Commission on May 5, 2015. This offering is being
made only by means of a prospectus. When available, copies of the
final prospectus relating to this offering may be obtained by
contacting: Piper Jaffray & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by
telephone at (800) 747-3924, or by email at prospectus@pjc.com, or
Stifel, Nicolaus & Company, Incorporated, One Montgomery
Street, Suite 3700, San Francisco, CA 94104, Attention: Syndicate,
by telephone at (415) 364-2720 or by email at
syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or
jurisdiction.
CONTACT: Thomas Mathers
Chief Executive Officer
CoLucid Pharmaceuticals, Inc.
(781) 365-2596
Hans Vitzthum
Managing Director
LifeSci Advisors, LLC.
(212) 915-2568
COLUCID PHARMACEUTICALS, INC. (NASDAQ:CLCD)
Historical Stock Chart
From Jun 2024 to Jul 2024
COLUCID PHARMACEUTICALS, INC. (NASDAQ:CLCD)
Historical Stock Chart
From Jul 2023 to Jul 2024